2例免疫检查点抑制剂联合化疗引发2型糖尿病个案报道  

Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors Combined with Chemotherapy

作　　者：肖平[1] 张琳琳[1] 王瑜[2] 孟凡路[1] 王鑫[1] 钟殿胜[1] Ping XIAO;Linlin ZHANG;Yu WANG;Fanlu MENG;Xin WANG;Diansheng ZHONG(Department of Medical Oncology,Tianjin Medical University General Hospital,Tianjin 300052,China;Department of Medical Endocrine Metabolism,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院肿瘤内科,天津300052 [2]天津医科大学总医院内分泌代谢科,天津300052

出　　处：《中国肺癌杂志》2022年第4期287-290,共4页Chinese Journal of Lung Cancer

基　　金：天津市教育委员会项目(No.2020KJ161)资助。

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)已经成为肿瘤治疗的重要手段,其在临床中的应用越来越广泛。ICIs引起的不良反应逐渐被认识,其中免疫治疗相关性糖尿病是罕见的不良反应,最常见的是1型糖尿病。随着ICIs联合化疗在肺癌患者中广泛应用,治疗过程中出现2型糖尿病的患者逐渐被发现,但是这部分患者后续继续应用ICIs维持治疗对血糖、ICIs治疗过程的影响尚不清楚。本文报道2例ICIs联合化疗期间新发的2型糖尿病,其中1例患者转为1型糖尿病,旨在增加对免疫治疗相关性糖尿病的认识。Immune checkpoint inhibitors(ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes.

关 键 词：免疫检查点抑制剂 不良反应 2型糖尿病 

分 类 号：R730.51[医药卫生—肿瘤] R587.1[医药卫生—临床医学]